v3.22.1
Stock-based Compensation - Stock Options and RSU Activity (Details)
 12 Months Ended
Dec. 31, 2021
$ / shares
shares
Stockholders Equity [Line Items]  
No. of options, Outstanding as of December 31, 2020 | shares 1,353,888
No. of options, Granted | shares 1,668,297
No. of options, Exercised/Vested | shares (8,334)
No. of options, Forfeited | shares (183,230)
No. of options, Expired | shares (3,750)
No. of options, Outstanding as of December 30, 2021 | shares 2,826,871
No. of options, Exercisable as of December 30, 2021 | shares 1,024,694
Weighted average grant date fair value, Balance at December 31, 2020 $ 3.82
Weighted average grant date fair value, Granted 1.56
Weighted average grant date fair value, Exercised/Vested 1.53
Weighted average grant date fair value, Forfeited 1.61
Weighted average grant date fair value, Expired 50.8
Weighted average grant date fair value, Balance at December 30, 2021 2.57
Weighted average grant date fair value, Exercisable at December 30, 2021 $ 3.81
RSUs  
Stockholders Equity [Line Items]  
No. of options, Outstanding as of December 31, 2020 | shares 0
No. of options, Granted | shares 1,349,167
No. of options, Exercised/Vested | shares (749,167)
No. of options, Forfeited | shares 0
No. of options, Expired | shares 0
No. of options, Outstanding as of December 30, 2021 | shares 600,000
Weighted average grant date fair value, Balance at December 31, 2020 $ 0
Weighted average grant date fair value, Granted 1.58
Weighted average grant date fair value, Exercised/Vested 1.54
Weighted average grant date fair value, Forfeited 0
Weighted average grant date fair value, Expired 0
Weighted average grant date fair value, Balance at December 30, 2021 $ 1.63
XpresTest RSAs  
Stockholders Equity [Line Items]  
No. of options, Outstanding as of December 31, 2020 | shares 28.75
No. of options, Granted | shares 120.00
No. of options, Exercised/Vested | shares (148.75)
No. of options, Outstanding as of December 30, 2021 | shares  
Weighted average grant date fair value, Balance at December 31, 2020 $ 11,390.35
Weighted average grant date fair value, Granted 5,227.20
Weighted average grant date fair value, Exercised/Vested 6,418.40
Weighted average grant date fair value, Balance at December 30, 2021  
Minimum [Member]  
Stockholders Equity [Line Items]  
Exercise price range, Outstanding as of December 31, 2020 1.53
Exercise price range, Granted 1.19
Exercise price range, Outstanding as of December 31, 2021 1.19
Exercise price range, Exercisable as of December 31, 2021 1.19
Maximum [Member]  
Stockholders Equity [Line Items]  
Exercise price range, Outstanding as of December 31, 2020 2,460.0
Exercise price range, Granted 1.61
Exercise price range, Outstanding as of December 31, 2021 2,460.0
Exercise price range, Exercisable as of December 31, 2021 $ 2,460.0